(Source: Bionomics Limited) Microsoft Word - ASX741 BNO Updated MT_CT 2015_announcement ABN 53 075 582 740 ASX ANNOUNCEMENT 4 November 2015 BIONOMICS TO PRESENT PRECLINCAL DATA ON BNC105 AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE Synergistic relationship seen with BNC105 and checkpoint inhibitors in preclinical models of colorectal cancer BNC105 also shown to suppress renal, breast and soft tissue sarcoma tumor growth in combination with evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, in preclinical models Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the...
↧